+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "AVN-101"

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 62 Pages
  • Global
From
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 70 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The AVN-101 market is a subset of the Central Nervous System (CNS) Drugs market. It is composed of drugs used to treat neurological disorders, such as Alzheimer's disease, Parkinson's disease, and epilepsy. These drugs are designed to improve cognitive function, reduce seizures, and improve motor control. They are typically administered orally or intravenously. The AVN-101 market is highly competitive, with many companies vying for market share. Companies in this market include AbbVie, AstraZeneca, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are engaged in research and development of new drugs, as well as marketing and distribution of existing drugs. They are also involved in clinical trials to test the efficacy and safety of their products. Show Less Read more